LSV Asset Management Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

LSV Asset Management reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,700 shares of the company’s stock after selling 1,300 shares during the quarter. LSV Asset Management’s holdings in Eli Lilly and Company were worth $26,639,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $27,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $36,000. Family CFO Inc purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC raised its stake in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $740.00 on Monday. The company has a market cap of $703.30 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.45 and a beta of 0.37. The firm’s fifty day simple moving average is $761.06 and its two-hundred day simple moving average is $672.28. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm posted $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LLY. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.